2-Chloroquinazoline → HCID 57662924, Verbindung

HRID 2402521

Reaktionsgleichung

Reaktionsgleichung von HRID 2402521
Cl[C:2]1[N:11]=[CH:10][C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[N:3]=1.[NH2:12][C:13]1[CH:14]=[C:15]2[C:19](=[CH:20][CH:21]=1)[C:18](=[O:22])[N:17]([C:23]1[C:28]([CH3:29])=[CH:27][CH:26]=[CH:25][C:24]=1[CH3:30])[C:16]2=[O:31]>C(O)CCC>[CH3:29][C:28]1[CH:27]=[CH:26][CH:25]=[C:24]([CH3:30])[C:23]=1[N:17]1[C:16](=[O:31])[C:15]2[C:19](=[CH:20][CH:21]=[C:13]([NH:12][C:2]3[N:11]=[C:10]([C:4]4[CH:9]=[CH:8][CH:7]=[CH:6][CH:5]=4)[C:9]4[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=4)[N:3]=3)[CH:14]=2)[C:18]1=[O:22]

Komponenten

4

Edukt 2

HCID 740542-ChloroquinazolineHCID 1240314-Amino-N-(2,6-dimethylphenyl)phthalimide

Produkt 1

HCID 57662924HCID 57662924, VerbindungAusbeute 42,5 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 2631-ButanolLösungsmittel2×

Versuchsvorschrift

A mixture of 2-chloroquinazoline (0.62 g, 2.6 mmol) and 5-amino-2-(2,6-dimethylphenyl)isoindoline-1,3-dione (0.69 g, 2.6 mmol) in n-butanol (10 mL) was heated at 120° C. until all of the butanol had evaporated. Additional butanol (10 mL) was added and the process repeated twice. After the reaction mixture was cooled, water was added (20 mL). A precipitate which formed was collected by suction filtration. N,N-Dimethylacetamide (5 mL) was added to dissolve the solid which was purified by preparative reverse-phase HPLC to give 2-(2,6-dimethylphenyl)-5-[(4-phenylquinazolin-2-yl)amino]-1H-isoindole-1,3(2H)-dione (0.26 g, 21%). 1H NMR (400 MHz, DMSO-d6): δ10.88 (s, 1H), 8.80 (m, 1H), 8.42 (m, 1H), 7.96 (m, 1H), 7.90 (m, 2H), 7.85 (m, 1H), 7.81 (m, 2H), 7.65 (m, 3H), 7.50 (m, 1H), 7.32 (m, 1H), 7.25 (m, 2H), 2.10 (s, 6H). MS (EI) for C30H22N4O2: 471.0 (MH+).

Aufarbeitung

  1. customhad evaporated
  2. additionAdditional butanol (10 mL) was added
  3. temperatureAfter the reaction mixture was cooled
  4. additionwater was added (20 mL)
  5. customA precipitate which formed
  6. filtrationwas collected by suction filtration
  7. additionN,N-Dimethylacetamide (5 mL) was added
  8. dissolutionto dissolve the solid which
  9. customwas purified by preparative reverse-phase HPLC

Quellen und Nachweise

ORD-Eintrag
ord-8d3427f72515459a9ad9c3d566beb54f
Quelldatensatz
uspto-grants-2014_08
Patentnummer
US08796294B2

Verknüpfte Notizen

Wird geladen…